Affiliation: University of Oxford
- Mediation of the proinflammatory cytokine response in rheumatoid arthritis and spondylarthritis by interactions between fibroblast-like synoviocytes and natural killer cellsAntoni Chan
Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
Arthritis Rheum 58:707-17. 2008..In the present study, we sought to determine whether the interaction between NK cells and FLS from SpA patients results in a proinflammatory response...
- Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritisA T Chan
Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford OX3 9DS, UK
Arthritis Rheum 52:3586-95. 2005..We therefore undertook the present study to determine the number and function of NK and T cells bearing KIR3DL2 in SpA...
- CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblastsAntoni Chan
Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, UK
J Immunol 179:89-94. 2007..Our data support a linear differentiation model of human NK development in which immature CD56(bright) NK cells can differentiate into CD56(dim) cells...
- Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptideSimon Kollnberger
MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford, UK
Eur J Immunol 37:1313-22. 2007..By contrast with HLA heterotrimers, B27(2) binding to KIR did not depend on the sequence of the bound peptide. Differences in KIR binding to classical HLA and B27(2) could be involved in the pathogenesis of spondyloarthritis...
- Update on the use of biologics in primary systemic vasculitidesChetan Mukhtyar
Botnar Research Center, University of Oxford, Oxford, UK
Expert Rev Clin Immunol 3:901-11. 2007..The risks and benefits of the use of biologics are discussed, together with future directions and predictions of these emerging therapies...